Last reviewed · How we verify
Havrix Junior
Havrix Junior is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.
Havrix Junior is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Prevention of hepatitis A infection in children aged 12 months to 18 years.
At a glance
| Generic name | Havrix Junior |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated viral vaccine |
| Target | Hepatitis A virus antigen |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) hepatitis A virus antigen, which triggers the body's adaptive immune response to generate protective antibodies and cellular immunity against hepatitis A without causing disease. This provides long-term protection against infection with wild-type hepatitis A virus. The junior formulation contains a lower antigen dose suitable for pediatric populations.
Approved indications
- Prevention of hepatitis A infection in children aged 12 months to 18 years
Common side effects
- Injection site soreness or swelling
- Fever
- Headache
- Fatigue
- Loss of appetite
Key clinical trials
- Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents (PHASE3)
- To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (PHASE3)
- To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs (PHASE3)
- An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children (PHASE3)
- Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™ (PHASE4)
- A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children (PHASE3)
- Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM (PHASE4)
- Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |